한글목차

이 보고서는 세계 강직성 척추염 시장을 조사했으며, 시장 개요와 함께 승인된 치료법, 파이프라인 동향, 향후 전망 등을 제공합니다.

목차

주요 요약

치료 알고리즘

조사 목적

TNF 억제제

• 시판 요법
  • Remicade (infliximab; Janssen Biotech/Merck & Co.); Enbrel (etanercept; Pfizer/Amgen); Simponi (golimumab; Janssen Biotech/Merck & Co.); Humira (adalimumab; AbbVie); Cimzia (certolizumab pegol; UCB) (12)

IL-17 억제제

• 승인 치료법
  • Cosentyx (secukinumab; Novartis)
  • Taltz (ixekizumab; Lilly)
  • Bimzelx (bimekizumab; UCB)
• 파이프라인 치료법
  • Izokibep (Acelyrin/Affibody)

JAK 억제제

• 승인 치료법
  • Rinvoq (upadacitinib; AbbVie)
  • Xeljanz (tofacitinib; Pfizer)
• 파이프라인 치료법
  • Jyseleca (filgotinib; Galapagos NV)

기타 작용기전

• 파이프라인 치료법
  • Namilumab (Amgen/Takeda/Izana)

향후의 치료 패러다임

부록

영문목차

What does the future AS therapy landscape look like? Will the domination of anti-TNFs continue? How do KOLs assess the potential of anti-IL17 strategies? Could a re-evaluation of safety concerns see wider use of JAK inhibitors such as AbbVie's Rinvoq and Pfizer's Xeljanz? What pipeline therapies could bring new treatment options? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to KOL Bulletins.

Table of Contents

Executive summary (8)

Treatment algorithm (1)

Research objectives (5)

TNF inhibitors (12)

• Marketed therapies (12)
  • Remicade (infliximab; Janssen Biotech/Merck & Co.); Enbrel (etanercept; Pfizer/Amgen); Simponi (golimumab; Janssen Biotech/Merck & Co.); Humira (adalimumab; AbbVie); Cimzia (certolizumab pegol; UCB) (12)

IL-17 inhibitors (34)

• Approved therapies (28)
  • Cosentyx (secukinumab; Novartis) (10)
  • Taltz (ixekizumab; Lilly) (9)
  • Bimzelx (bimekizumab; UCB) (9)
• Pipeline drugs (6)
  • Izokibep (Acelyrin/Affibody) (6)

JAK inhibitors (18)

• Approved therapies (14)
  • Rinvoq (upadacitinib; AbbVie) (8)
  • Xeljanz (tofacitinib; Pfizer) (6)
• Pipeline therapies (4)
  • Jyseleca (filgotinib; Galapagos NV) (4)

Other mechanisms of action (6)

• Pipeline therapies (6)
  • Namilumab (Amgen/Takeda/Izana) (6)

Future treatment paradigm (11)

• Key insights summary (11)

Appendix (4)

• KOL details (4)
  • KOLs from North America (1)
  • KOLs from Europe (2)